CAMBRIDGE, Mass.--(BUSINESS WIRE)--Unum Therapeutics, a clinical-stage biopharmaceutical company focused on the development of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer, today announced the appointment of Christiana Stamoulis to the additional role of President. Ms. Stamoulis has been Unum’s Chief Financial Officer and Head of Corporate Development since joining the Company in January 2015. In her role as President and Chief Financial Officer, Ms. Stamoulis is responsible for Unum’s business functions including finance, corporate and business development, corporate strategy, legal, investor relations and corporate communications.
“Christiana has been instrumental in driving Unum’s financial strategy, capital-raising, and corporate development and strategic initiatives over the last three years,” said Chuck Wilson, PhD, Chief Executive Officer of Unum. “Her appointment as President is a fitting and well-earned recognition of her role and the enormous impact she has had in helping to drive Unum’s rapid progress.”
Ms. Stamoulis was recently recognized as one of FiercePharma’s 2017 Fiercest Women in Life Sciences for driving Unum’s partnership with Seattle Genetics and its $65M Series B financing round and for her ongoing contribution to the rapid transformation of Unum from a very early start-up into a dynamic, well capitalized clinical-stage company.
Ms. Stamoulis has served as Unum’s Chief Financial Officer and Head of Corporate Development since January 2015. Prior to joining Unum, Ms. Stamoulis was the Senior Vice President of Corporate Strategy and Business Development and a member of the Executive Team at Vertex Pharmaceuticals, Inc. Prior to Vertex, she served as a Managing Director in the Investment Banking division of Citigroup where she led the building of its U.S. Life Sciences investment banking practice. Prior to her role at Citigroup, she was a senior investment banker in the Healthcare group of the Investment Banking division of Goldman, Sachs & Co. where she spent the majority of her investment banking career. Ms. Stamoulis started her career as a strategy consultant at The Boston Consulting Group. Ms. Stamoulis serves on the Board of Directors of Hologic Inc. and Kyn Therapeutics. Ms. Stamoulis received two bachelor degrees from the Massachusetts Institute of Technology (MIT) and her MBA from MIT’s Sloan School of Management.
About Unum Therapeutics
Unum Therapeutics uses its proprietary antibody-coupled T cell receptor (ACTR) technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum is actively building a pipeline of ACTR programs in combination with a wide range of proprietary, tumor-targeting antibodies for use in both hematologic and solid tumor cancers. The Company is headquartered in Cambridge, MA. For more information, visit www.unumrx.com/.
